Daily Sepsis Research Analysis
Analyzed 69 papers and selected 3 impactful papers.
Summary
Three studies advance sepsis research across prognosis and prevention: a MIMIC-IV analysis links early vital-sign trajectories to high-risk phenotypes and proposes data-driven blood gas ranges in sepsis-associated thrombocytopenia; a large PSM cohort shows GLP-1 receptor agonists are associated with fewer pulmonary/systemic infections and sepsis in diabetic gastroparesis; and a SIC-focused study integrates baseline and dynamic RDW trajectories with external validation to improve 30-day mortality prediction.
Research Themes
- Trajectory-based sepsis phenotyping and personalized physiological targets
- Hematologic biomarkers (RDW) and dynamic risk stratification in sepsis-induced coagulopathy
- Metabolic therapy (GLP-1 RA) linked to reduced infectious complications and sepsis risk
Selected Articles
1. From vital sign trajectories to data-driven targets: defining exploratory blood gas ranges in sepsis-associated thrombocytopenia.
Using MIMIC-IV, the authors identified three early 12-hour vital-sign trajectory clusters in SATP; the high HR/RR and low SpO₂ cluster had significantly higher ICU, 28-, 90-, and 365-day mortality. Within this high-risk subphenotype, nonlinear associations yielded exploratory blood gas ranges linked to the lowest predicted ICU mortality, proposing a trajectory-to-targets framework for early personalized management.
Impact: Introduces a novel trajectory-based phenotyping approach coupled with data-driven physiological targets in SATP, potentially bridging early risk recognition to actionable management hypotheses.
Clinical Implications: Clinicians can use early vital-sign trajectories to identify high-risk SATP patients and consider the reported blood gas ranges as hypothesis-generating references when individualizing early ICU management; these are not prescriptive targets.
Key Findings
- Three 12-hour ICU trajectory clusters were identified; the high HR/RR and low SpO₂ cluster had higher ICU (HR 1.40), 28-day (HR 1.56), 90-day (HR 1.43), and 365-day (HR 1.33) mortality.
- Restricted cubic splines showed nonlinear relationships between blood gas values and ICU mortality in the high-risk subgroup.
- Model-derived exploratory ranges associated with lowest predicted mortality included pH 7.32–7.64, PO₂ 25.00–324.32 mmHg, PCO₂ 21.94–53.74 mmHg, and lactate 0.6–7.49 mmol/L.
Methodological Strengths
- Group-based multi-trajectory modeling on high-resolution early ICU data
- Advanced nonlinear modeling (RCS) and PDP to quantify physiologic ranges
Limitations
- Retrospective single-database design limits causal inference and generalizability
- Proposed blood gas ranges are hypothesis-generating and broad; potential confounding by treatment and missingness
Future Directions: Prospective, multi-center validation of trajectory phenotypes and testing whether protocolized physiology targets improve outcomes in SATP.
BACKGROUND: The early in-intensive care unit (ICU) phase is critical for sepsis-associated thrombocytopenia (SATP) patients, yet the prognostic value of their initial physiological trajectory remains underexplored. We aimed to identify distinct subgroups based on vital sign trajectories following ICU admission and to investigate their differential outcomes and subsequent blood gas management needs. METHODS: This retrospective study utilized the MIMIC-IV database. Adults with SATP were included. Group-based multi-trajectory modeling (GBMTM) was applied to hourly vital signs (including heart rate, blood pressure, respiratory rate, and SpO₂) from the first 12 h of ICU stay to identify subgroups. Mortality risk was assessed using Cox regression, with the lowest-risk cluster as the reference. Within the identified high-risk sub-phenotype, the nonlinear relationships between blood gas ranges and ICU mortality were analyzed with restricted cubic splines (RCS). Finally, multivariable partial dependence plots (PDP) were employed to quantify the optimal ranges for blood gas parameters, defined as those associated with the lowest ranges of predicted mortality risk for this subgroup. RESULTS: The analysis of initial 12-h physiological trajectories classified patients into three subgroups: Cluster 1 (characterized by elevated blood pressure), Cluster 2 (marked by high heart rates and respiratory rates with low SpO₂), and Cluster 3 (low blood pressure with high SpO₂). Cluster 2 was identified as the high-risk subgroup, demonstrating significantly increased mortality risks compared with Cluster 3: ICU mortality (HR = 1.40; 95% CI: 1.13-1.73), 28-day mortality (HR = 1.56; 95% CI: 1.30-1.88), 90-day mortality (HR = 1.43; 95% CI: 1.21-1.67), and 365-day mortality (HR = 1.33; 95% CI: 1.15-1.54). Within Cluster 2, restricted cubic spline analyses revealed nonlinear relationships between blood gas parameters and ICU mortality. Using partial dependence plot analysis, we identified model-derived ranges of blood gas values associated with the lowest predicted mortality risk, which may serve as exploratory physiological references for this high-risk subgroup: pH 7.32-7.64, PO₂ 25.00-324.32 mmHg, PCO₂ 21.94-53.74 mmHg, lactate 0.6-7.49 mmol/L, base excess -7.47 to 23.00 mEq/L, and total CO₂ 43.47-56.00 mEq/L. These ranges, though broad, reflect the inherent physiological variability during the early ICU phase and should be interpreted as hypothesis-generating parameters rather than strict clinical targets. CONCLUSION: Early vital sign trajectories during the first 12 h in the ICU effectively stratify SATP patients into prognostic subgroups. For the high-risk subphenotype, we further delineated model-derived physiological ranges of blood gas parameters, creating a "trajectory-to-targets" framework. This approach offers a hypothesis-generating strategy for transitioning from early risk identification to personalized physiological insights in the critical early phase of ICU care.
2. Glucagon-like Peptide-1 Receptor Agonist Therapy and Risk of Pulmonary and Systemic Infections in Diabetic Gastroparesis: A Propensity-Matched Cohort Study.
In a 1:1 propensity-matched cohort of 46,742 adults with diabetes and gastroparesis, GLP-1 RA exposure was associated with lower risks of pneumonitis, pneumonia, mechanical ventilation, sepsis (HR 1.44 for non-users vs users), and bacteremia. Outcomes were assessed from 180 days post-index, suggesting systemic benefits that may outweigh delayed gastric emptying concerns.
Impact: Provides large-scale, matched real-world evidence that GLP-1 RAs may reduce serious infections and sepsis in a population at elevated aspiration/infection risk.
Clinical Implications: In patients with diabetic gastroparesis, GLP-1 RA therapy may confer infectious risk reduction; clinicians can prioritize comprehensive risk–benefit discussions and avoid reflex discontinuation solely due to gastric-emptying concerns.
Key Findings
- After 1:1 PSM (23,371 per cohort), non-GLP-1 users had higher pneumonitis (HR 1.76) and pneumonia (HR 1.34).
- Systemic infection endpoints were reduced with GLP-1 RA exposure: sepsis (HR 1.44 for non-users vs users) and bacteremia (HR 1.46).
- Mechanical ventilation was less frequent among GLP-1 RA users (HR 1.63 for non-users vs users).
Methodological Strengths
- Very large, multi-institutional dataset with rigorous 1:1 propensity score matching
- Comprehensive assessment of pulmonary and systemic infection outcomes from a prespecified time window
Limitations
- Observational design with potential residual confounding and indication bias
- Medication exposure intensity, adherence, and specific agents/doses not fully characterized
Future Directions: Prospective studies to confirm causality and to delineate mechanisms (anti-inflammatory, metabolic, microbiome) by which GLP-1 RAs may reduce infection and sepsis risk.
INTRODUCTION: Diabetic gastroparesis increases the risk of aspiration, pneumonia, and sepsis, yet the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on these outcomes is uncertain because of their gastric-emptying effects. METHODS: We performed a retrospective cohort study using the TriNetX Global Research Network. Adults (≥18 years) with diabetes mellitus and gastroparesis were identified and divided into two cohorts based on GLP-1 RA exposure. Propensity score matching (1:1) balanced demographics, comorbidities, and antidiabetic medications, yielding 23,371 patients per cohort. Outcomes, assessed from 180 days after index, included pneumonia, pneumonitis, mechanical ventilation, ventilator-associated pneumonia, sepsis, bacteremia, empyema, lung abscess, acute respiratory distress syndrome (ARDS), and need for enteral feeding. Risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. RESULTS: Compared with GLP-1 users, non-GLP-1 patients had higher incidences of pneumonitis (3.6% vs. 2.5%; HR 1.76, 95% CI 1.58-1.95), pneumonia (13.2% vs. 12.2%; HR 1.34, 95% CI 1.27-1.41), mechanical ventilation (4.4% vs. 3.3%; HR 1.63, 95% CI 1.49-1.79), sepsis (12.8% vs. 11.1%; HR 1.44, 95% CI 1.37-1.52), and bacteremia (5.2% vs. 4.4%; HR 1.46, 95% CI 1.35-1.59) (all CONCLUSIONS: In patients with diabetes and gastroparesis, GLP-1 RA therapy was associated with significantly fewer pulmonary and systemic infectious complications. These data suggest that the systemic benefits of GLP-1 RAs may outweigh concerns regarding delayed gastric emptying in this high-risk population.
3. Baseline RDW combined with dynamic trajectory: Predictive value for 30-day all-cause mortality in patients with sepsis-induced coagulopathy and development of a nomogram.
In 2,531 SIC patients, higher baseline RDW and a rapidly ascending RDW trajectory independently predicted 30-day mortality, with mortality rising across RDW tertiles and HRs >2 for the highest tertile and high-rise trajectory. An RDW-integrated nomogram achieved strong discrimination (C-index 0.805; AUC 0.813) and was externally validated in 317 patients.
Impact: Demonstrates that a simple, widely available hematologic parameter and its trajectory add prognostic value in SIC and provides a practical, validated nomogram for bedside risk stratification.
Clinical Implications: Incorporating baseline RDW and its early trajectory into SIC assessment may refine 30-day mortality risk estimation and guide intensity of monitoring and supportive care.
Key Findings
- Mortality increased across RDW tertiles (Q1 4.5% vs Q2 10.7% vs Q3 22.7%; P<0.001); highest tertile independently predicted 30-day mortality (adjusted HR 2.666).
- LCGMM identified two RDW trajectories; the rapidly ascending trajectory had 31.1% mortality vs 10.0% for stable low (adjusted HR 2.522).
- An RDW-integrated nomogram showed strong performance (C-index 0.805; AUC 0.813) with external validation in 317 patients.
Methodological Strengths
- Large retrospective cohort with advanced trajectory modeling (LCGMM) and multivariable Cox/RCS analyses
- External validation and machine-learning feature selection (Boruta, LASSO)
Limitations
- Retrospective single-database derivation limits causal inference; RDW is non-specific and influenced by comorbidities
- External validation cohort (n=317) is modest and from a single center, potentially limiting generalizability
Future Directions: Prospective validation and integration with multi-biomarker panels and dynamic physiologic data to enhance prognostic calibration and clinical utility.
OBJECTIVE: Sepsis-induced coagulopathy (SIC) is associated with high mortality. This study aimed to explore the predictive value of baseline red blood cell distribution width (RDW) and its dynamic trajectory for 30-day all-cause mortality in SIC patients, and to develop a practical nomogram. METHODS: A retrospective cohort study was conducted on 2531 SIC patients from the MIMIC-IV v3.1 database. Patients were grouped by baseline RDW tertiles, and RDW dynamic trajectories were constructed via Latent Class Growth Mixture Model (LCGMM). Kaplan-Meier analysis, Cox proportional hazards regression, and Restricted Cubic Spline (RCS) model were applied to assess the association between RDW and 30-day mortality. A nomogram was built via Boruta algorithm and Lasso regression, with external validation in 317 patients from a Shanghai tertiary hospital. RESULTS: 30-day mortality increased with elevated baseline RDW (Q1: 4.5% vs. Q2: 10.7% vs. Q3: 22.7%, P < 0.001), and Q3 was an independent risk factor (adjusted HR = 2.666, 95%CI: 1.854-3.834). RDW> about 15% correlated with sustained mortality risk. LCGMM identified two trajectories (stable low-level Traj0, rapidly ascending Traj1), with Traj1 showing higher mortality (31.1% vs. 10.0%, adjusted HR = 2.522). The nomogram integrating RDW and clinical indicators demonstrated good discrimination (C-index = 0.805, AUC = 0.813) and utility. CONCLUSION: High baseline RDW and rapidly ascending RDW trajectory are independent risk factors for 30-day mortality in SIC patients. The nomogram enables convenient and accurate risk stratification and prognostic evaluation.